Tirzepatide (Mounjaro) is the most effective anti-obesity medication currently available, with average weight loss of 20%+ in clinical trials. Available on private prescription from our consultant specialist in Naas, Co. Kildare.
What Is Tirzepatide?
Tirzepatide (brand name Mounjaro) is a once-weekly injectable medication that activates two hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual action makes it the most effective injectable weight-loss treatment currently available.
In the SURMOUNT-1 clinical trial (NEJM, 2022), patients taking 15mg weekly achieved average weight loss of 20.9% over 72 weeks. Some participants lost more than 25%. It also significantly improves blood glucose, making it particularly effective in type 2 diabetes or insulin resistance.
Who Is Tirzepatide For?
Dosing
Dosing principles:
Dose escalation depends on individual clinical need, response, adverse effects and tolerability — this is not a fixed, automatic schedule. Your consultant will agree the right pace with you.
Content last reviewed: 31 July 2026.
How It Works
Tirzepatide, sold as Mounjaro, is a once-weekly injection that activates two gut-hormone receptors — GLP-1 and GIP. Acting on both is what distinguishes it from semaglutide (Wegovy, Ozempic), which acts on GLP-1 alone. The combined effect slows stomach emptying, reduces appetite and food-related cravings, and improves the body's insulin response, so people eat less without the constant hunger that undermines most diets, and blood glucose improves at the same time.
The weight-loss evidence comes from the SURMOUNT programme. In SURMOUNT-1, adults with obesity and without diabetes taking the 15 mg dose lost on average about 20.9% of body weight over 72 weeks, compared with about 3% on placebo, and SURMOUNT-4 showed that continuing treatment maintained the loss while stopping it led to substantial regain. In type 2 diabetes, the SURPASS trials showed large reductions in HbA1c alongside weight loss. Tirzepatide is licensed both for chronic weight management, in people with a BMI of 30 or above (or 27 or above with a weight-related condition), and for type 2 diabetes.
Prescribing & Monitoring
Starting Treatment
On Treatment
Start Tirzepatide
Dr Kazmi, Consultant Endocrinologist (IMC 213626), Naas Co. Kildare. Saturday & Sunday appointments. Full medical assessment included. Self-referral accepted.
Yes. Dr Kazmi (Consultant Endocrinologist, IMC 213626) at Naas Cardiology & Endocrinology Clinic prescribes tirzepatide (Mounjaro) following a full medical assessment. Saturday & Sunday clinics in Naas, Co. Kildare.
In the SURMOUNT-1 trial, participants taking 15mg tirzepatide weekly lost an average of 20.9% of body weight over 72 weeks. Some patients lost more than 25%. Results vary by individual.
Mounjaro (tirzepatide) acts on both GLP-1 and GIP receptors, producing greater average weight loss (~20%) than Wegovy (semaglutide, ~15%). Wegovy has proven cardiovascular benefit (SELECT trial). A specialist consultation determines which is right for you.
For chronic weight management, tirzepatide is licensed for adults with a body mass index of 30 kg/m² or above, or 27 kg/m² or above where there is a weight-related condition such as type 2 diabetes, high blood pressure, obstructive sleep apnoea or fatty liver disease. Dr Kazmi assesses each person individually — BMI alone does not decide suitability. It is not prescribed in pregnancy or when trying to conceive, or where there is a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and caution applies with a history of pancreatitis or significant gallbladder disease.
In the SURMOUNT-1 trial of adults with obesity without diabetes, average weight loss over 72 weeks was about 15% on the 5 mg dose and about 21% on the 15 mg dose, versus about 3% on placebo. Loss is gradual: it begins within the first few weeks, continues over roughly 12 to 18 months, and then plateaus. Individual results vary widely, and the outcome depends heavily on staying on an effective dose and combining the medication with changes to eating pattern and activity. In type 2 diabetes the average weight loss is somewhat lower, alongside a substantial fall in HbA1c.
Both are once-weekly injections for weight management. Wegovy (semaglutide 2.4 mg) acts on the GLP-1 receptor only and produced average weight loss of about 15% in its STEP trials; it also has proven cardiovascular benefit versus placebo in people with established heart disease and obesity from the SELECT trial. Mounjaro (tirzepatide) acts on both GLP-1 and GIP receptors and produced greater average weight loss, around 21% at the top dose, in SURMOUNT-1; its cardiovascular-outcome trial (SURPASS-CVOT, published in the New England Journal of Medicine) showed non-inferiority to dulaglutide on cardiovascular events in Type 2 diabetes, an active-comparator rather than placebo-controlled result. Choice depends on your goals, your medical history and tolerability, and is decided at the consultation.
Where the assessment shows tirzepatide is appropriate and safe for you, a private prescription can be issued at the initial consultation, with a clear titration schedule and a follow-up plan. The consultation fee is €230 for the initial appointment and €150 for follow-ups; the medication itself is bought separately from a pharmacy and is not included in the consultation fee. This is a self-pay clinic — some insurers reimburse outpatient consultant fees depending on your policy, which you should confirm with them directly. The clinic does not supply the medication itself and does not endorse buying it from unregulated online sources.